{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,18]],"date-time":"2026-10-18T15:07:28Z","timestamp":1792336048956,"version":"4.4.0"},"reference-count":16,"publisher":"Springer Science and Business Media LLC","issue":"1","funder":[{"DOI":"10.13039\/501100000289","name":"Cancer Research UK","doi-asserted-by":"publisher","award":["C18027\/A13762"],"award-info":[{"award-number":["C18027\/A13762"]}],"id":[{"id":"10.13039\/501100000289","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004337","name":"Roche","doi-asserted-by":"publisher","award":["ML29281"],"award-info":[{"award-number":["ML29281"]}],"id":[{"id":"10.13039\/100004337","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Trials"],"published-print":{"date-parts":[[2017,12]]},"DOI":"10.1186\/s13063-017-2107-0","type":"journal-article","created":{"date-parts":[[2017,7,26]],"date-time":"2017-07-26T13:07:22Z","timestamp":1501074442000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["GA101 (obinutuzumab) monocLonal Antibody as Consolidation Therapy In CLL (GALACTIC) trial: study protocol for a phase II\/III randomised controlled trial"],"prefix":"10.1186","volume":"18","author":[{"given":"Jamie B.","family":"Oughton","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Collett","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dena R.","family":"Howard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Hockaday","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Talha","family":"Munir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathryn","family":"McMahon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucy","family":"McParland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claire","family":"Dimbleby","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Phillips","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andy C.","family":"Rawstron","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Hillmen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,7,26]]},"reference":[{"issue":"26","key":"2107_CR1","doi-asserted-by":"crossref","first-page":"3559","DOI":"10.1200\/JCO.2010.33.8061","volume":"29","author":"K Fischer","year":"2011","unstructured":"Fischer K, Cramer P, Busch R, Stilgenbauer S, Bahlo J, Schweighofer CD, et al. Bendamustine combined with rituximab in patients with relapsed and\/or refractory chronic lymphocytic leukemia: a multicenter phase II trial of the German Chronic Lymphocytic Leukemia Study Group. J Clin Oncol. 2011;29(26):3559\u201366.","journal-title":"J Clin Oncol"},{"issue":"9747","key":"2107_CR2","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1016\/S0140-6736(10)61512-7","volume":"376","author":"P Hillmen","year":"2010","unstructured":"Hillmen P. Chronic lymphocytic leukaemia\u2014moving towards cure? Lancet. 2010;376(9747):1122\u20134.","journal-title":"Lancet"},{"issue":"22","key":"2107_CR3","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1182\/blood.V114.22.540.540","volume":"114","author":"M Kwok","year":"2009","unstructured":"Kwok M, Rawstron AC, Varghese A, Hillmen P. Minimal residual disease is a predictor for progression-free and overall survival in chronic lymphocytic leukemia (CLL) that is independent of the type or line of therapy [abstract]. Blood. 2009;114(22):540.","journal-title":"Blood"},{"issue":"4","key":"2107_CR4","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1111\/bjh.14342","volume":"176","author":"AM Varghese","year":"2017","unstructured":"Varghese AM, Howard DR, Pocock C, Rawstron AC, Follows G, McCarthy H, et al. Eradication of minimal residual disease improves overall and progression-free survival in patients with chronic lymphocytic leukaemia, evidence from NCRN CLL207: a phase II trial assessing alemtuzumab consolidation. Br J Haematol. 2017;176(4):573\u201382.","journal-title":"Br J Haematol"},{"issue":"12","key":"2107_CR5","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1056\/NEJMoa1313984","volume":"370","author":"V Goede","year":"2014","unstructured":"Goede V, Fischer K, Busch R, Engelke A, Eichhorst B, Wendtner CM, et al. Obinutuzumab plus chlorambucil in patients with CLL and coexisting conditions. N Engl J Med. 2014;370(12):1101\u201310.","journal-title":"N Engl J Med"},{"issue":"1","key":"2107_CR6","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1158\/1535-7163.MCT-10-0385","volume":"10","author":"S Dalle","year":"2011","unstructured":"Dalle S, Reslan L, Besseyre De Horts T, Herveau S, Herting F, Plesa A, et al. Preclinical studies on the mechanism of action and the anti-lymphoma activity of the novel anti-CD20 antibody GA101. Mol Cancer Ther. 2011;10(1):178\u201385.","journal-title":"Mol Cancer Ther"},{"issue":"Suppl 2","key":"2107_CR7","first-page":"39","volume":"92","author":"G Cartron","year":"2011","unstructured":"Cartron G, Morschhauser F, Thieblemont C, Lamy T, Milpied J, Tilly M, et al. Results from a phase II study of obinutuzumab (GA101) monotherapy in relapsed\/refractory chronic lymphocytic leukemia (CLL) [abstract 0101]. Haematologica. 2011;92 Suppl 2:39\u201340.","journal-title":"Haematologica"},{"key":"2107_CR8","unstructured":"Cartron GC, Thieblemont C, Solal-C\u00e9ligny P, Morschhauser F, Haioun C, Bouabdallah R, et al. Results from a phase II study (BO20999) of RO5072759 (GA101) monotherapy in relapsed\/refractory aggressive non-Hodgkin\u2019s lymphoma [abstract 144]. Ann Oncol. 2011;22(Suppl 4)."},{"issue":"22","key":"2107_CR9","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1182\/blood.V114.22.884.884","volume":"114","author":"F Morschhauser","year":"2009","unstructured":"Morschhauser F, Cartron G, Lamy T, Milpied NJ, Thieblemont C, Tilly H, et al. Phase I study of RO507259 (GA101) in relapsed\/refractory chronic lymphocytic leukemia [abstract]. Blood. 2009;114(22):884.","journal-title":"Blood"},{"issue":"12","key":"2107_CR10","doi-asserted-by":"crossref","first-page":"5446","DOI":"10.1182\/blood-2007-06-093906","volume":"111","author":"M Hallek","year":"2008","unstructured":"Hallek M, Cheson BD, Catovsky D, Caligaris-Cappio F, Dighiero G, D\u00f6hner H, et al. Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines. Blood. 2008;111(12):5446\u201356.","journal-title":"Blood"},{"issue":"3","key":"2107_CR11","doi-asserted-by":"crossref","first-page":"549","DOI":"10.2307\/2530245","volume":"35","author":"PC O\u2019Brien","year":"1979","unstructured":"O\u2019Brien PC, Fleming TR. A multiple testing procedure for clinical trials. Biometrics. 1979;35(3):549\u201356.","journal-title":"Biometrics"},{"issue":"1","key":"2107_CR12","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0197-2456(89)90015-9","volume":"10","author":"R Simon","year":"1989","unstructured":"Simon R. Optimal two-stage designs for phase II clinical trials. Control Clin Trials. 1989;10(1):1\u201310.","journal-title":"Control Clin Trials"},{"key":"2107_CR13","unstructured":"Common Terminology Criteria for Adverse Events (CTCAE). http:\/\/evs.nci.nih.gov\/ftp1\/CTCAE\/CTCAE_4.03_2010-06-14_QuickReference_8.5x11.pdf . Accessed 14 June 2010."},{"issue":"4","key":"2107_CR14","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1038\/leu.2015.313","volume":"30","author":"AC Rawstron","year":"2016","unstructured":"Rawstron AC, Fazi C, Agathangelidis A, Villamor N, Letestu R, Nomdedeu J, et al. A complementary role of multiparameter flow cytometry and high-throughput sequencing for minimal residual disease detection in chronic lymphocytic leukemia: an European Research Initiative on CLL study. Leukemia. 2016;30(4):929\u201336.","journal-title":"Leukemia"},{"issue":"2","key":"2107_CR15","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1111\/j.2517-6161.1972.tb00899.x","volume":"34","author":"D Cox","year":"1972","unstructured":"Cox D. Regression models and life-tables. J R Stat Soc Ser B. 1972;34(2):187\u2013200.","journal-title":"J R Stat Soc Ser B"},{"key":"2107_CR16","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1080\/01621459.1958.10501452","volume":"53","author":"E Kaplan","year":"1958","unstructured":"Kaplan E, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1958;53:457\u201381.","journal-title":"J Am Stat Assoc"}],"container-title":["Trials"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13063-017-2107-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,25]],"date-time":"2024-06-25T20:07:24Z","timestamp":1719346044000},"score":1,"resource":{"primary":{"URL":"http:\/\/trialsjournal.biomedcentral.com\/articles\/10.1186\/s13063-017-2107-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,7,26]]},"references-count":16,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2017,12]]}},"alternative-id":["2107"],"URL":"https:\/\/doi.org\/10.1186\/s13063-017-2107-0","relation":{},"ISSN":["1745-6215"],"issn-type":[{"value":"1745-6215","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,7,26]]},"article-number":"353"}}